Funding

Massachusetts -Based ProFound Therapeutics Receives $35M Investment

Aug 28, 2026 | By Devin Jacobs

SUMMARY

ProFound Therapeutics received up to $35M from the Gates Foundation.
The funding will support AI and drug discovery.
ProFound Therapeutics develops new medicines and drug targets.

ProFound Therapeutics, a Cambridge, MA-based developer of medicines harnessing the expanded human proteome, has received an investment of up to $35 million from the Gates Foundation, including an initial investment of $20 million.

The funding will support its ProFoundry platform and AI capabilities to discover new biomarkers, protein drugs and drug targets for preeclampsia and eclampsia.

Funding Snapshot

Metric	Details
Investment	Up to $35M
Initial Investment	$20M
Valuation	Not disclosed
Company	ProFound Therapeutics
Sector	Biotechnology / Drug Discovery
Headquarters	Cambridge, Massachusetts, USA

RECOMMENDED FOR YOU

PA-based MedRisk Acquired Medata

Devin Jacobs

Jan 11, 2024

Funding

Altesa BioSciences Raises $75M in Series B Funding

Startuprise

Feb 19, 2026

Funding

Funding Wrap of the Week | American Startups Funding Roundup | June 2 – June 7

Devin Jacobs

Jun 8, 2024

About ProFound Therapeutics

ProFound Therapeutics discovers previously hidden proteins within the expanded human proteome to identify new drug targets and develop novel protein-based medicines.

Core offerings include:

Protein discovery
Drug target identification
Biomarker discovery
Protein drug development

Core Technologies / Products / Services

Capability/Product	Application/Use Case
ProFoundry Platform	Identifies novel proteins and their functions
Protein Detection	Discovers previously hidden proteins
Computational Methods	Analyzes protein connectivity and biology
Agentic AI	Supports discovery of biomarkers and drug targets

Leadership Comments

"Preeclampsia and eclampsia are devastating conditions for mothers and families across the globe, yet little is known about the underlying biology driving these diseases and therapeutic options remain limited," said John Lepore, M.D., CEO of ProFound Therapeutics and Flagship Pioneering CEO-Partner. "The expanded proteome represents a vast and largely untapped resource for identifying novel protein drugs, drug targets, and biomarkers for diseases with significant unmet need.